BE1011045A3 - Compositions pharmaceutiques pour la liberation controlee de substances actives. - Google Patents
Compositions pharmaceutiques pour la liberation controlee de substances actives. Download PDFInfo
- Publication number
- BE1011045A3 BE1011045A3 BE9700225A BE9700225A BE1011045A3 BE 1011045 A3 BE1011045 A3 BE 1011045A3 BE 9700225 A BE9700225 A BE 9700225A BE 9700225 A BE9700225 A BE 9700225A BE 1011045 A3 BE1011045 A3 BE 1011045A3
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- active substance
- release
- pharmaceutical composition
- composition according
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 41
- 238000013270 controlled release Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 43
- 239000011159 matrix material Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000003513 alkali Substances 0.000 claims abstract description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 3
- 150000001447 alkali salts Chemical class 0.000 claims abstract description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims abstract description 3
- 229910021538 borax Inorganic materials 0.000 claims abstract description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims abstract description 3
- 150000007524 organic acids Chemical class 0.000 claims abstract description 3
- 235000021317 phosphate Nutrition 0.000 claims abstract description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract description 3
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000005985 organic acids Nutrition 0.000 claims abstract 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 23
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 22
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 22
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 22
- 229960000240 hydrocodone Drugs 0.000 claims description 22
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 22
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 21
- 229960003908 pseudoephedrine Drugs 0.000 claims description 21
- 239000002610 basifying agent Substances 0.000 claims description 19
- 239000008240 homogeneous mixture Substances 0.000 claims description 16
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 16
- 230000002035 prolonged effect Effects 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960000363 trapidil Drugs 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 238000013265 extended release Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 150000004679 hydroxides Chemical class 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 abstract description 5
- 239000001913 cellulose Substances 0.000 abstract description 5
- 229920002125 Sokalan® Polymers 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 239000004584 polyacrylic acid Substances 0.000 abstract description 2
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- 229920003091 Methocel™ Polymers 0.000 description 9
- 229910052749 magnesium Inorganic materials 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 9
- 229910002012 Aerosil® Inorganic materials 0.000 description 8
- -1 polyethylene Polymers 0.000 description 8
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229960001803 cetirizine Drugs 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000007907 direct compression Methods 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000019589 hardness Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 229920003095 Methocel™ K15M Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000283222 Physeter catodon Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical class C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940045860 white wax Drugs 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 description 1
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE9700225A BE1011045A3 (fr) | 1997-03-14 | 1997-03-14 | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| RU99119084/14A RU2179017C2 (ru) | 1997-03-14 | 1998-03-13 | Фармацевтическая композиция для контролируемого высвобождения активных веществ (варианты) и способ ее получения (варианты) |
| AT98909235T ATE275943T1 (de) | 1997-03-14 | 1998-03-13 | Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen |
| JP53995798A JP2001524950A (ja) | 1997-03-14 | 1998-03-13 | 活性物質の制御された放出のための薬剤組成物 |
| IL13129298A IL131292A (en) | 1997-03-14 | 1998-03-13 | Pharmaceutical preparations for controlled release of active ingredients |
| ES98909235T ES2229483T3 (es) | 1997-03-14 | 1998-03-13 | Composiciones farmaceuticas para la liberacion controlada de sustancias activas. |
| PL98335832A PL190735B1 (pl) | 1997-03-14 | 1998-03-13 | Kompozycja farmaceutyczna i sposób wytwarzania tej kompozycji farmaceutycznej |
| US09/381,044 US6699502B1 (en) | 1997-03-14 | 1998-03-13 | Pharmaceutical compositions for controlled release of active substances |
| AU63873/98A AU736052B2 (en) | 1997-03-14 | 1998-03-13 | Pharmaceutical compositions for controlled release of active substances |
| PCT/BE1998/000033 WO1998041194A1 (fr) | 1997-03-14 | 1998-03-13 | Compositions pharmaceutiques pour la liberation controlee de substances actives |
| RO99-00963A RO120602B1 (ro) | 1997-03-14 | 1998-03-13 | Compoziţie farmaceutică pentru eliberarea controlată a substanţelor active şi procedeu pentru prepararea acesteia |
| HK00105542.2A HK1026152B (en) | 1997-03-14 | 1998-03-13 | Pharmaceutical compositions for controlled release of active substances |
| BR9808239-6A BR9808239A (pt) | 1997-03-14 | 1998-03-13 | Composição farmacêutica administrável por via oral, e, processo de preparação da mesma |
| DE69826290T DE69826290T2 (de) | 1997-03-14 | 1998-03-13 | Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen |
| EP98909235A EP1007005B1 (fr) | 1997-03-14 | 1998-03-13 | Compositions pharmaceutiques pour la liberation controlee de substances actives |
| IDW991007A ID22980A (id) | 1997-03-14 | 1998-03-13 | Komposisi-komposisi farmasi untuk pelepasan zat-zat aktif yang dikontrol |
| CN98803222A CN1126536C (zh) | 1997-03-14 | 1998-03-13 | 用于控制释放活性物质的药物组合物 |
| NZ337345A NZ337345A (en) | 1997-03-14 | 1998-03-13 | Pharmaceutical compositions for controlled release of active substances comprising an alkalinizing agent |
| CA002283133A CA2283133C (fr) | 1997-03-14 | 1998-03-13 | Compositions pharmaceutiques pour la liberation controlee de substances actives |
| KR10-1999-7008365A KR100500775B1 (ko) | 1997-03-14 | 1998-03-13 | 활성 물질의 방출을 조절하기 위한 약제 조성물 |
| US10/055,962 US20020110596A1 (en) | 1997-03-14 | 2002-01-28 | Pharmaceutical compositions for the controlled release of active substances |
| US10/607,047 US7083807B2 (en) | 1997-03-14 | 2003-06-27 | Pharmaceutical compositions for the controlled release of active substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE9700225A BE1011045A3 (fr) | 1997-03-14 | 1997-03-14 | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1011045A3 true BE1011045A3 (fr) | 1999-04-06 |
Family
ID=3890403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE9700225A BE1011045A3 (fr) | 1997-03-14 | 1997-03-14 | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6699502B1 (https=) |
| EP (1) | EP1007005B1 (https=) |
| JP (1) | JP2001524950A (https=) |
| KR (1) | KR100500775B1 (https=) |
| CN (1) | CN1126536C (https=) |
| AT (1) | ATE275943T1 (https=) |
| AU (1) | AU736052B2 (https=) |
| BE (1) | BE1011045A3 (https=) |
| BR (1) | BR9808239A (https=) |
| CA (1) | CA2283133C (https=) |
| DE (1) | DE69826290T2 (https=) |
| ES (1) | ES2229483T3 (https=) |
| ID (1) | ID22980A (https=) |
| IL (1) | IL131292A (https=) |
| NZ (1) | NZ337345A (https=) |
| PL (1) | PL190735B1 (https=) |
| RO (1) | RO120602B1 (https=) |
| RU (1) | RU2179017C2 (https=) |
| WO (1) | WO1998041194A1 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1050306A (ja) * | 1996-07-31 | 1998-02-20 | Toyota Autom Loom Works Ltd | 水素吸蔵合金電極の製造方法 |
| BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
| WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| JP2001107258A (ja) * | 1999-10-06 | 2001-04-17 | Hitachi Ltd | 無電解銅めっき方法とめっき装置および多層配線基板 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| AU764453B2 (en) * | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| EP1118321A1 (fr) * | 2000-01-14 | 2001-07-25 | Ucb, S.A. | Compositions pharmaceutiques solides pour la libération contrôlée de substances actives |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
| MXPA03003895A (es) | 2000-10-30 | 2003-07-28 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada. |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| DE60232445D1 (de) | 2001-06-28 | 2009-07-09 | Ucb Farchim Sa | Cetirizin und pseudoephedrin enthaltende tablette |
| CA2451519C (en) * | 2001-06-28 | 2007-11-06 | Ucb, Farchim, S.A. | Tablet comprising cetirizine and pseudoephedrine |
| US20030092724A1 (en) * | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
| ES2285088T3 (es) * | 2002-01-09 | 2007-11-16 | Ucb Farchim S.A. | Composiciones farmaceuticas de liberacion modificada. |
| WO2003084511A1 (en) * | 2002-04-04 | 2003-10-16 | Pfizer Products Inc. | Palatable chewable tablet |
| EP1545468A4 (en) * | 2002-09-20 | 2007-06-20 | Alpharma Inc | SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE |
| US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| DE60322577D1 (de) * | 2002-12-06 | 2008-09-11 | Ucb Farchim Sa | Tablette enthaltend efletirizin und pseudoephedrin |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| US20060029664A1 (en) * | 2004-08-04 | 2006-02-09 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing carbetapentane and another drug |
| US20050281875A1 (en) * | 2003-12-17 | 2005-12-22 | Sovereign Pharmaceuticals, Ltd. | Promethazine containing dosage form |
| US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
| US20050232986A1 (en) * | 2003-12-17 | 2005-10-20 | David Brown | Dosage form containing promethazine and another drug |
| US9492541B2 (en) * | 2004-09-14 | 2016-11-15 | Sovereign Pharmaceuticals, Llc | Phenylepherine containing dosage form |
| US20050232987A1 (en) * | 2004-03-12 | 2005-10-20 | Viswanathan Srinivasan | Dosage form containing a morphine derivative and another drug |
| US7897172B2 (en) * | 2004-05-18 | 2011-03-01 | L. Perrigo Company | Tablets exhibiting reduced drug release variability |
| US9308164B2 (en) | 2004-06-30 | 2016-04-12 | Sovereign Pharmaceuticals, Llc | Hyoscyamine dosage form |
| US20070003622A1 (en) * | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
| US9592197B2 (en) * | 2004-12-16 | 2017-03-14 | Sovereign Pharmaceuticals, Llc | Dosage form containing diphenhydramine and another drug |
| WO2006022996A2 (en) * | 2004-08-04 | 2006-03-02 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
| US7529255B2 (en) * | 2005-04-21 | 2009-05-05 | Microsoft Corporation | Peer-to-peer multicasting using multiple transport protocols |
| KR20080030546A (ko) * | 2005-07-26 | 2008-04-04 | 유씨비 파마, 에스.에이. | 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법 |
| DK1940467T3 (da) | 2005-09-09 | 2017-02-13 | Paladin Labs Inc | Lægemiddelsammensætning med langvarig frigivelse |
| CN101252932B (zh) * | 2005-09-09 | 2012-10-03 | 安吉利尼莱博法姆有限责任公司 | 用于一天给药一次的曲唑酮组合物 |
| EP1991207A2 (en) * | 2006-01-21 | 2008-11-19 | Abbott GmbH & Co. KG | Dosage form and method for the delivery of drugs of abuse |
| US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
| US20090317355A1 (en) * | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| US20100172989A1 (en) * | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| KR100753480B1 (ko) * | 2006-01-27 | 2007-08-31 | 씨제이 주식회사 | 잘토프로펜 함유 서방성 정제 및 그 제조방법 |
| US20070253927A1 (en) * | 2006-04-13 | 2007-11-01 | Gwenaelle Jegou | Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator |
| WO2007141743A2 (en) * | 2006-06-06 | 2007-12-13 | Ranbaxy Laboratories Limited | A tablet dosage form comprising cetirizine and pseudoephedrine |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| MX2008016349A (es) * | 2006-06-19 | 2009-01-28 | Accu Break Technologies Inc | Formas segmentadas de dosificacion farmaceutica. |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| JP5597394B2 (ja) | 2006-09-25 | 2014-10-01 | コーニンクレッカ フィリップス エヌ ヴェ | 回転ｘ線撮像における完全軌道に対する対象物の移動 |
| EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| JP2010510320A (ja) | 2006-11-21 | 2010-04-02 | マクニール−ピーピーシー・インコーポレーテツド | 改変型放出鎮痛性懸濁液 |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| KR20100069685A (ko) * | 2007-10-16 | 2010-06-24 | 라보팜 인코포레이트 | 아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물 |
| EP2217279B1 (en) * | 2007-11-21 | 2017-11-01 | The Procter & Gamble Company | Preparations useful for treatment of cough |
| US8486448B2 (en) | 2007-12-17 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| ES2620672T3 (es) | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
| US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
| AU2009327312A1 (en) | 2008-12-16 | 2011-08-04 | Labopharm Europe Limited | Misuse preventative, controlled release formulation |
| WO2010078486A2 (en) | 2008-12-31 | 2010-07-08 | Upsher-Smith Laboratories, Inc. | Opioid-containing oral pharmaceutical compositions and methods |
| WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
| CA2773521C (en) | 2009-09-17 | 2017-01-24 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug |
| CA2798702A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholresistant metoprolol-containing extended-release oral dosage forms |
| CN102302497A (zh) * | 2011-05-18 | 2012-01-04 | 天圣制药集团股份有限公司 | 一种治疗过敏性鼻炎的制剂及其制备方法 |
| CA2899492C (en) | 2013-02-13 | 2019-09-17 | The Procter & Gamble Company | Anise flavored medication |
| KR102070076B1 (ko) * | 2013-05-03 | 2020-01-29 | 주식회사 제닉 | 탄산 함유 입자를 포함하는 필름 |
| WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| SG11201607511WA (en) | 2014-03-11 | 2016-10-28 | Redhill Biopharma Ltd | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms |
| JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| RU2687715C1 (ru) * | 2018-05-07 | 2019-05-15 | Федеральное государственное бюджетное учреждение науки Институт горного дела Дальневосточного отделения Российской академии наук | Способ комбинированной разработки россыпных месторождений золота |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| KR102073185B1 (ko) * | 2019-07-16 | 2020-02-04 | (주)위바이오트리 | 활성성분을 포함하는 변성 다중층 수산화물 구조체를 포함하는 금속 수산화물 복합체 및 이의 제조 방법 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396404A1 (en) * | 1989-05-03 | 1990-11-07 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| WO1994006416A1 (en) * | 1992-09-24 | 1994-03-31 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
| WO1994009761A1 (en) * | 1992-10-23 | 1994-05-11 | Schering Corporation | Stable extended release oral dosage composition |
| WO1995034291A1 (en) * | 1994-06-15 | 1995-12-21 | Dumex-Alpharma A/S | Pellets |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US477033A (en) * | 1892-06-14 | Bicycle | ||
| US4684516A (en) | 1983-08-01 | 1987-08-04 | Alra Laboratories, Inc. | Sustained release tablets and method of making same |
| DE3681348D1 (de) | 1985-06-11 | 1991-10-17 | Teijin Ltd | Oral-arzneizubereitung mit retardwirkung. |
| DE3524572A1 (de) | 1985-07-10 | 1987-01-15 | Thomae Gmbh Dr K | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung |
| US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| JPS6396126A (ja) | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
| IT1201136B (it) | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
| GB8724763D0 (en) | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| IE60383B1 (en) * | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
| MX9300110A (es) * | 1992-01-13 | 1994-07-29 | Gerhard Gergely | Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion. |
| US5411748A (en) | 1992-10-22 | 1995-05-02 | Song Moon K | Prostate extract supplemented with zinc |
| RU2065299C1 (ru) * | 1994-07-15 | 1996-08-20 | Акционерное общество закрытого типа "Олвик" | Ноотропное и транквилизирующее средство |
| EP0811374A1 (en) * | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
| EP0951279A1 (en) * | 1997-01-10 | 1999-10-27 | Abbott Laboratories | Tablet for the controlled release of active agents |
| BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
-
1997
- 1997-03-14 BE BE9700225A patent/BE1011045A3/fr not_active IP Right Cessation
-
1998
- 1998-03-13 AU AU63873/98A patent/AU736052B2/en not_active Ceased
- 1998-03-13 BR BR9808239-6A patent/BR9808239A/pt not_active Application Discontinuation
- 1998-03-13 KR KR10-1999-7008365A patent/KR100500775B1/ko not_active Expired - Fee Related
- 1998-03-13 ES ES98909235T patent/ES2229483T3/es not_active Expired - Lifetime
- 1998-03-13 NZ NZ337345A patent/NZ337345A/xx unknown
- 1998-03-13 PL PL98335832A patent/PL190735B1/pl not_active IP Right Cessation
- 1998-03-13 RO RO99-00963A patent/RO120602B1/ro unknown
- 1998-03-13 JP JP53995798A patent/JP2001524950A/ja not_active Ceased
- 1998-03-13 ID IDW991007A patent/ID22980A/id unknown
- 1998-03-13 CN CN98803222A patent/CN1126536C/zh not_active Expired - Fee Related
- 1998-03-13 CA CA002283133A patent/CA2283133C/fr not_active Expired - Fee Related
- 1998-03-13 DE DE69826290T patent/DE69826290T2/de not_active Expired - Fee Related
- 1998-03-13 EP EP98909235A patent/EP1007005B1/fr not_active Expired - Lifetime
- 1998-03-13 US US09/381,044 patent/US6699502B1/en not_active Expired - Lifetime
- 1998-03-13 RU RU99119084/14A patent/RU2179017C2/ru not_active IP Right Cessation
- 1998-03-13 AT AT98909235T patent/ATE275943T1/de not_active IP Right Cessation
- 1998-03-13 IL IL13129298A patent/IL131292A/en active IP Right Grant
- 1998-03-13 WO PCT/BE1998/000033 patent/WO1998041194A1/fr not_active Ceased
-
2002
- 2002-01-28 US US10/055,962 patent/US20020110596A1/en not_active Abandoned
-
2003
- 2003-06-27 US US10/607,047 patent/US7083807B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396404A1 (en) * | 1989-05-03 | 1990-11-07 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| WO1994006416A1 (en) * | 1992-09-24 | 1994-03-31 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
| WO1994009761A1 (en) * | 1992-10-23 | 1994-05-11 | Schering Corporation | Stable extended release oral dosage composition |
| WO1995034291A1 (en) * | 1994-06-15 | 1995-12-21 | Dumex-Alpharma A/S | Pellets |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001524950A (ja) | 2001-12-04 |
| EP1007005A1 (fr) | 2000-06-14 |
| AU6387398A (en) | 1998-10-12 |
| KR100500775B1 (ko) | 2005-07-12 |
| DE69826290D1 (de) | 2004-10-21 |
| HK1026152A1 (en) | 2000-12-08 |
| ATE275943T1 (de) | 2004-10-15 |
| CA2283133C (fr) | 2006-07-25 |
| ES2229483T3 (es) | 2005-04-16 |
| DE69826290T2 (de) | 2005-02-17 |
| EP1007005B1 (fr) | 2004-09-15 |
| CN1250371A (zh) | 2000-04-12 |
| KR20000076269A (ko) | 2000-12-26 |
| US20020110596A1 (en) | 2002-08-15 |
| WO1998041194A1 (fr) | 1998-09-24 |
| CN1126536C (zh) | 2003-11-05 |
| RU2179017C2 (ru) | 2002-02-10 |
| ID22980A (id) | 1999-12-23 |
| IL131292A (en) | 2004-07-25 |
| US7083807B2 (en) | 2006-08-01 |
| US20040086563A1 (en) | 2004-05-06 |
| IL131292A0 (en) | 2001-01-28 |
| RO120602B1 (ro) | 2006-05-30 |
| US6699502B1 (en) | 2004-03-02 |
| AU736052B2 (en) | 2001-07-26 |
| NZ337345A (en) | 2000-04-28 |
| CA2283133A1 (fr) | 1998-09-24 |
| PL335832A1 (en) | 2000-05-22 |
| BR9808239A (pt) | 2000-05-16 |
| PL190735B1 (pl) | 2005-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1011045A3 (fr) | Compositions pharmaceutiques pour la liberation controlee de substances actives. | |
| BE1014328A7 (fr) | Composition pharmaceutique orale a liberation controlee. | |
| EP1121099B1 (fr) | Composition pharmaceutique a residence gastrique et a liberation controlee | |
| US8501228B2 (en) | Stable compositions of famotidine and ibuprofen | |
| US7569612B1 (en) | Methods of use of fenofibric acid | |
| EP1631263B1 (fr) | Comprime orodispersible multicouche | |
| FR2855756A1 (fr) | Comprime orodispersible multicouche | |
| FR2713484A1 (fr) | Nouvelle composition pharmaceutique à libération contrôlée par diffusion osmotique et son procédé de préparation. | |
| FR2792198A1 (fr) | Formulations pharmaceutiques nouvelles comprenant de l'amoxycilline et du clavulanate de potassium | |
| JP2009543885A (ja) | イブプロフェンの投与のための方法および医薬 | |
| EP1118321A1 (fr) | Compositions pharmaceutiques solides pour la libération contrôlée de substances actives | |
| EP2640364B9 (fr) | Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme médicament dans le traitement et/ou la prévention des lithiases urinaires et des maladies liées | |
| CA2577361C (fr) | Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif | |
| EP1465607B1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
| EP1904037A1 (fr) | Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph | |
| EP3975998A1 (fr) | Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles | |
| MXPA99008148A (en) | Pharmaceutical compositions for controlled release of active substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: S.A.*UCB Effective date: 20020331 |